FDA Delays Decision on Moderna Vaccine for Children Aged 12 and Up: Company

A medical volunteer prepares the Moderna COVID-19 vaccine for a patient at Lestonnac Free Clinic in Orange, Calif., on March 9, 2021. John Fredricks/The Epoch Times

The U.S. Food and Drug Administration (FDA) delayed a decision on whether to approve Moderna’s CCP virus vaccine for children aged 12 and older, according to the pharmaceutical giant on Sunday.

The health regulator is investigating the risk of myocarditis, a form of heart inflammation, in children aged 12 to 17, Moderna’s statement said. The review may not be completed before January of next year, the company said.